1-20 of 38
Term: Adult Clinical Trials – Immunologic
Volume: 20
Issue: suppl_6
Save search
Sort by
Journal Article

ATIM-31. PHASE I STUDY OF TUMOR TREATMENT FIELDS AND A PERSONALIZED MUTATION-DERIVED TUMOR VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

PDF
Adilia Hormigo and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi8, https://doi.org/10.1093/neuonc/noy148.026
Published: 05 November 2018
Journal Article

ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS

PDF
David Reardon and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi8, https://doi.org/10.1093/neuonc/noy148.027
Published: 05 November 2018
Journal Article

ATIM-34. TARGETING THE CD200 CHECKPOINT FOR THE FIGHT AGAINST CENTRAL NERVOUS SYSTEM TUMORS

PDF
Michael Olin and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi9, https://doi.org/10.1093/neuonc/noy148.029
Published: 05 November 2018
Journal Article

ATIM-35. VXM01 PHASE I STUDY IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA – FINAL RESULTS

PDF
Wolfgang Wick and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi9, https://doi.org/10.1093/neuonc/noy148.030
Published: 05 November 2018
Journal Article

ATIM-37. SAFETY RUN-IN RESULTS OF A PHASE I/II STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF ATEZOLIZUMAB (ATEZO; aPDL1) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

PDF
Shiao-Pei Weathers and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi9–vi10, https://doi.org/10.1093/neuonc/noy148.032
Published: 05 November 2018
Journal Article

ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

PDF
David Reardon and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi10, https://doi.org/10.1093/neuonc/noy148.033
Published: 05 November 2018
Journal Article

ATIM-40. HIGH RATE OF OBJECTIVE ANTI-TUMOR RESPONSE IN 9 PATIENTS WITH GLIOBLASTOMA AFTER VIRO-IMMUNOTHERAPY WITH ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB AND PD-1 CHECKPOINT BLOCKADE

PDF
Karsten Geletneky and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi10, https://doi.org/10.1093/neuonc/noy148.035
Published: 05 November 2018
Journal Article

ATIM-41. PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) For Newly Diagnosed Glioblastoma

PDF
Manmeet Ahluwalia and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi10–vi11, https://doi.org/10.1093/neuonc/noy148.036
Published: 05 November 2018
Journal Article

ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS

PDF
John de Groot and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi2, https://doi.org/10.1093/neuonc/noy148.004
Published: 05 November 2018
Journal Article

ATIM-13. ASUNERCEPT PLUS RADIOTHERAPY IN RELAPSED GLIOBLASTOMA. UPDATE ON FIVE YEARS OVERALL SURVIVAL OF STUDY NCT01071837 AND DEVELOPMENT OF A POPULATION-PK - TUMOR GROWTH INHIBITION - SURVIVAL MODEL

PDF
Harald Ficke and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi3, https://doi.org/10.1093/neuonc/noy148.008
Published: 05 November 2018
Journal Article

ATIM-14. CMV gB/pp65 eVLPs FORMULATED WITH GM-CSF AS A THERAPEUTIC VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM)

PDF
Fabio Iwamoto and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi3, https://doi.org/10.1093/neuonc/noy148.009
Published: 05 November 2018
Journal Article

ATIM-15. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULTS WITH RECURRENT GLIOBLASTOMA: DOSE DETERMINATION WITH UPDATED OVERALL SURVIVAL

PDF
E Antonio Chiocca and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi3–vi4, https://doi.org/10.1093/neuonc/noy148.010
Published: 05 November 2018
Journal Article

ATIM-18. A PHASE I TRIAL OF VACCINATION WITH AUTOLOGOUS DENDRITIC CELLS PULSED WITH LYSATE DERIVED FROM AN ALLOGENEIC GLIOBLASTOMA STEMLIKE CELL LINE FOR PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA

PDF
Jethro Hu and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi4, https://doi.org/10.1093/neuonc/noy148.013
Published: 05 November 2018
Journal Article

ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

PDF
Mark Gilbert and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi7, https://doi.org/10.1093/neuonc/noy148.024
Published: 05 November 2018
Journal Article

ATIM-10. A PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS CMV-SPECIFIC CYTOTOXIC T CELLS (CMV-TC) FOR GLIOBLASTOMA: DOSE ESCALATION AND CORRELATIVE RESULTS

PDF
Marta Penas-Prado and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi2–vi3, https://doi.org/10.1093/neuonc/noy148.006
Published: 05 November 2018
Journal Article

ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS

PDF
Michael Platten and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi8–vi9, https://doi.org/10.1093/neuonc/noy148.028
Published: 05 November 2018
Journal Article

ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG)

PDF
Annick Desjardins and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi9, https://doi.org/10.1093/neuonc/noy148.031
Published: 05 November 2018
Journal Article

ATIM-03. TTFIELDS AND PULSED BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA: A PHASE 2 STUDY

PDF
David Tran and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi1, https://doi.org/10.1093/neuonc/noy148.001
Published: 05 November 2018
Journal Article

ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM)

PDF
Mustafa Khasraw and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi4, https://doi.org/10.1093/neuonc/noy148.011
Published: 05 November 2018
Journal Article

ATIM-17. PEMBROLIZUMAB BLOCKS PD-1 ON CAR T CELLS ADMINISTERED INTRAVENTRICULARLY TO GLIOBLASTOMA PATIENTS

PDF
Jana Portnow and others
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi4, https://doi.org/10.1093/neuonc/noy148.012
Published: 05 November 2018